Back

In-hospital course of patients with heart failure with Improved ejection fraction in the DELIVER Trial

12 May 2024 (16:00 - 16:45)
Organised by: Logo
Congress Presentation Part of: Acute heart failure - epidemiology, prognosis, outcome 3 Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Maria Pabon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Obesity and clinical outcomes in acute decompensated heart failure according to left and right ventricular systolic function
Doctor D. Cocianni (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Impacts of heat exposure after the rainy season on heart failure in the elderly: linear and nonlinear associations
Doctor R. Fujimoto (Tsuyama, JP)
Abstract Slides Video
Presentation thumbnail
Weight loss during hospitalization for heart failure while receiving intravenous loop diuretic is associated with lower risk of rehospitalization regardless BMI: data from the SwedeHF registry
Mr M. Erhardsson (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Precision in prognostication: a comprehensive comparison of risk scores in the setting of cardiogenic shock
Doctor S. Azevedo (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Characteristics, treatment, and outcomes of early vs. late enrolees of the STRONG-HF trial.
Doctor M. Arrigo (Lugano, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Acute heart failure - epidemiology, prognosis, outcome 3

The Event

Event poster

Heart Failure 2024

12 May 2024 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Influence of achieved LVEF on efficacy of dapagliflozin in patients with heart failure with improved ejection fraction: the DELIVER trial
thumbnail
Congress Presentation
DELIVER
thumbnail
Congress Presentation
Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources